Zoetis Inc. (ZTS) Return on Equity (ROE): 81.75%
Is Zoetis Inc.’s return on equity (ROE) high or low?
Zoetis Inc.'s return on equity (ROE) of 81.75% is 55% above its 5-year average of 52.60%, near the high end of its 5-year range (43.46%–80.25%).
The return on equity (ROE) for Zoetis Inc. (ZTS) is 81.75% as of Wednesday, June 10, 2026. It is above its 12-month average by 23.52% (66.19%).
ZTS Return on Equity (ROE) Chart
ZTS Average Return on Equity (ROE) Chart
ZTS Current vs Average Return on Equity (ROE) Chart
ZTS Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
81.75%
RETURN ON EQUITY (ROE) AVG TTM
66.19%
RETURN ON EQUITY (ROE) AVG 3Y
56.82%
RETURN ON EQUITY (ROE) AVG 5Y
52.60%
RETURN ON EQUITY (ROE) AVG 10Y
52.01%
RETURN ON EQUITY (ROE) AVG 15Y
43.18%
RETURN ON EQUITY (ROE) AVG 20Y
40.64%
CURRENT VS TTM AVG
+23.52%
CURRENT VS 3Y AVG
+43.88%
CURRENT VS 5Y AVG
+55.43%
CURRENT VS 10Y AVG
+57.19%
CURRENT VS 15Y AVG
+89.33%
CURRENT VS 20Y AVG
+101.16%
ZTS Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | — | 81.75% | 66.19% | 56.82% | 52.60% |
| Centene Corporation (CNC) | $31.94B | -30.07% | -10.46% | -1.37% | 1.10% |
| Agilent Technologies, Inc. (A) | $37.17B | 19.85% | 20.59% | 21.51% | 20.54% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 22.26% | 21.77% | 21.17% | 17.55% |
| DexCom, Inc. (DXCM) | $29.24B | 31.47% | 28.93% | 25.01% | 22.95% |
| Biogen Inc. (BIIB) | $29.00B | 7.36% | 8.42% | 11.86% | 16.52% |
| Veeva Systems Inc. (VEEV) | $26.73B | 12.89% | 12.42% | 12.32% | 13.45% |
| Humana Inc. (HUM) | $43.78B | 6.08% | 7.05% | 11.93% | 15.09% |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 70.38% | 60.82% | 72.53% | 81.69% |
| Waters Corporation (WAT) | $23.83B | 2.94% | 29.98% | 64.02% | 111.55% |
Return Analysis
ROE
81.8%
ROA
17.4%
Zoetis Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Zoetis Inc. (ZTS)?
- The return on equity (ROE) for ZTS stock is 81.75%.
- Is Zoetis Inc.'s return on equity (ROE) high or low?
- Zoetis Inc.'s return on equity (ROE) of 81.75% is 55% above its 5-year average of 52.60%, near the high end of its 5-year range (43.46%–80.25%).
- What is the TTM average return on equity (ROE) for Zoetis Inc. (ZTS)?
- The TTM average return on equity (ROE) for ZTS stock is 66.19%.
- What is the 3Y average return on equity (ROE) for Zoetis Inc. (ZTS)?
- The 3Y average return on equity (ROE) for ZTS stock is 56.82%.
- What is the 5Y average return on equity (ROE) for Zoetis Inc. (ZTS)?
- The 5Y average return on equity (ROE) for ZTS stock is 52.60%.
- What is the 10Y average return on equity (ROE) for Zoetis Inc. (ZTS)?
- The 10Y average return on equity (ROE) for ZTS stock is 52.01%.
- What is the 15Y average return on equity (ROE) for Zoetis Inc. (ZTS)?
- The 15Y average return on equity (ROE) for ZTS stock is 43.18%.
- What is the 20Y average return on equity (ROE) for Zoetis Inc. (ZTS)?
- The 20Y average return on equity (ROE) for ZTS stock is 40.64%.
Zoetis Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 80.25% |
| 2024-12-31 | 52.12% |
| 2023-12-31 | 46.91% |
| 2022-12-31 | 47.99% |
| 2021-12-31 | 44.84% |
| 2020-12-31 | 43.46% |
| 2019-12-31 | 55.39% |
| 2018-12-31 | 65.35% |
| 2017-12-31 | 48.81% |
| 2016-12-31 | 55.21% |
| 2015-12-31 | 31.74% |
| 2014-12-31 | 44.47% |
| 2013-12-31 | 53.62% |
| 2012-12-31 | 10.83% |
| 2011-12-31 | 6.59% |
| 2010-12-31 | 3.29% |
| 2009-12-31 | 0.00% |
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck